Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome
AssigneeBiogen MA Inc.
InventorShibeshih Mitiku BELACHEW
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for administering disease-modifying antibody therapies to asymptomatic and/or early-stage multiple sclerosis patients, including Radiologically Isolated Syndrome patients, based on the identification and/or co-localization of slowly expanding lesions and paramagnetic rim lesions in magnetic resonance images from said patients.
Claims19
A method of treating Radiologically Isolated Syndrome in a patient in need thereof comprising administering a therapeutically effective amount of a disease-modifying antibody therapy to said patient, wherein said patient has at least one phase rim lesion (PRL) in at least one susceptibility-weighted magnetic resonance image (MRI), or the patient has at least one slowly expanding lesion (SEL) in at least one T1-weighted/T2-weighted MRI.
A method of reducing and/or treating chronic active white matter lesions in an early-stage and/or asymptomatic MS patient comprising administering a therapeutically effective amount of a disease-modifying antibody therapy to said patient, wherein said patient has at least one PRL in at least one susceptibility-weighted MRI, or the patient has at least one SEL in at least one T1-weighted/T2-weighted MRI.
The method of any preceding claim, wherein the SEL is detected using a machine-learning based classifier that discriminates acute from chronic MS lesions and/or SEL from non-SEL using single time-point non-contrast T1- and T2-weighted MRI.
The method of any preceding claim, wherein said disease-modifying antibody therapy is selected from natalizumab, BIIB107 and ocrelizumab.
The method of any preceding claim, wherein the disease-modifying antibody therapy is natalizumab.
A method for reducing and/or treating chronic lesion activity in an asymptomatic and/or early-stage MS patient (e.g. having no relapse events) comprising a) identifying at least one phase rim lesion (PRL) in at least one susceptibility-weighted magnetic resonance image from a patient known or suspected of having chronic lesion activity, b) identifying at least one slowly-expanding lesion (SEL) in at least one T1-weighted/T2-weighted MRI from said patient;
- c) determining if the at least one PRL co-localizes with the at least one SEL in said patient, and/or vice-versa, and d) in the event of co-localization initiating treatment with a disease-modifying antibody therapy.
Dependencies are inferred from the claim text.